131 related articles for article (PubMed ID: 36627144)
1. Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer.
Karbach J; Kiselicki D; Brand K; Wahle C; Sinelnikov E; Gustavus D; Hoffmeister H; Prisack HB; Atmaca A; Jäger E
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36627144
[TBL] [Abstract][Full Text] [Related]
2. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
3. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Matsuzaki J; Gnjatic S; Mhawech-Fauceglia P; Beck A; Miller A; Tsuji T; Eppolito C; Qian F; Lele S; Shrikant P; Old LJ; Odunsi K
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7875-80. PubMed ID: 20385810
[TBL] [Abstract][Full Text] [Related]
5. Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells.
Kim S; Park CI; Lee S; Choi HR; Kim CH
Front Immunol; 2023; 14():1062365. PubMed ID: 36793716
[TBL] [Abstract][Full Text] [Related]
6. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
Moon EK; Ranganathan R; Eruslanov E; Kim S; Newick K; O'Brien S; Lo A; Liu X; Zhao Y; Albelda SM
Clin Cancer Res; 2016 Jan; 22(2):436-47. PubMed ID: 26324743
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
Stadtmauer EA; Faitg TH; Lowther DE; Badros AZ; Chagin K; Dengel K; Iyengar M; Melchiori L; Navenot JM; Norry E; Trivedi T; Wang R; Binder GK; Amado R; Rapoport AP
Blood Adv; 2019 Jul; 3(13):2022-2034. PubMed ID: 31289029
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
9. Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.
Merhi M; Raza A; Inchakalody VP; Siveen KS; Kumar D; Sahir F; Mestiri S; Hydrose S; Allahverdi N; Jalis M; Relecom A; Al Zaidan L; Hamid MSE; Mostafa M; Gul ARZ; Uddin S; Al Homsi M; Dermime S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32913031
[TBL] [Abstract][Full Text] [Related]
10. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
Joseph J; Nathenson MJ; Trinh VA; Malik K; Nowell E; Carter K; Weathers SP; Demetri GD; Araujo D; Conley AP
J Immunother Cancer; 2019 Nov; 7(1):296. PubMed ID: 31703609
[TBL] [Abstract][Full Text] [Related]
11. Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.
Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Muzikansky A; Kalil J; Festa-Neto C; Duncan LM
J Immunol Res; 2015; 2015():761378. PubMed ID: 25954764
[TBL] [Abstract][Full Text] [Related]
12. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
[TBL] [Abstract][Full Text] [Related]
13. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H
J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289
[TBL] [Abstract][Full Text] [Related]
14. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
15. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
16. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
Kitano S; Tsuji T; Liu C; Hirschhorn-Cymerman D; Kyi C; Mu Z; Allison JP; Gnjatic S; Yuan JD; Wolchok JD
Cancer Immunol Res; 2013 Oct; 1(4):235-44. PubMed ID: 24396833
[TBL] [Abstract][Full Text] [Related]
18. Identification of NY-ESO-1
Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF
Front Immunol; 2021; 12():644520. PubMed ID: 33833762
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.
Everson RG; Antonios JP; Lisiero DN; Soto H; Scharnweber R; Garrett MC; Yong WH; Li N; Li G; Kruse CA; Liau LM; Prins RM
Neuro Oncol; 2016 Mar; 18(3):368-78. PubMed ID: 26330563
[TBL] [Abstract][Full Text] [Related]
20. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
